Manufacturer
Janssen
Contents
Ibrutinib
Indication
Adult patients w/ relapsed or refractory mantle cell lymphoma (MCL), previously untreated chronic lymphocytic leukaemia (CLL) & lymphocytic leukaemia who have received at least 1 prior therapy.
Instruction
May be taken with or without food: Take at the same time each day. Swallow whole with water do not open/break/chew. Do not take w/ grapefruit juice or Seville oranges.
Drug interaction
Increased exposure w/ strong, moderate or mild CYP3A4 inhibitors. Decreased plasma conc w/ CYP3A4 inducers eg, carbamazepine, rifampicin, phenytoin. Reduced efficacy w/ St. John's wort-containing prep. Drugs w/ narrow therapeutic range eg, dihydroergotamine, ergotamine, fentanyl, cyclosporine, sirolimus, tacrolimus; P-gp or BCRP substrates eg, digoxin or methotrexate. Reduced exposure to CYP2B6 substrates eg, efavirenz, bupropion.
Malaysia
